FDA Approves Intravenous Formulation Of Pfizer’s Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension

Medical News Today -- Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations.